idecabtagene vicleucel + lenalidomide

**Idecabtagene vicleucel + lenalidomide** is a combination therapy under clinical investigation for newly diagnosed multiple myeloma (NDMM) patients who have achieved a suboptimal response after autologous stem cell transplantation (ASCT)[1][3][5][7]. **Idecabtagene vicleucel** is a CAR T-cell therapy where a patient's T cells are extracted and genetically engineered to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), leading to direct recognition and lysis of myeloma cells[2][4]. **Lenalidomide** is an immunomodulatory drug that induces tumor cell death and disrupts tumor cell interactions within the bone marrow microenvironment. The combination aims to leverage synergies between CAR T-cell immune targeting and lenalidomide's immunomodulatory, anti-angiogenic, and anti-proliferative effects to potentially improve outcomes versus lenalidomide alone as maintenance after ASCT[1][5].

Other names

idecabtagene vicleucel + lenalidomideide-cel + lenalidomide